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Our understanding of the natural history of hepatitis B virus
(HBV) infection and the potential for therapy of the resultant dis-
ease is continuously improving. New data have become available
since the previous EASL Clinical Practice Guidelines (CPGs) pre-
pared in 2008 and published in early 2009 [1]. The objective of
this manuscript is to update the recommendations for the opti-
mal management of chronic HBV infection. The CPGs do not fully
address prevention including vaccination. In addition, despite the
increasing knowledge, areas of uncertainty still exist and there-
fore clinicians, patients, and public health authorities must con-
tinue to make choices on the basis of the evolving evidence.Context
Epidemiology and public health burden
Approximately one third of the world’s population has serological
evidence of past or present infection with HBV and 350–400 mil-
lion people are chronic HBV surface antigen (HBsAg) carriers. The
spectrum of disease and natural history of chronic HBV infection
are diverse and variable, ranging from an inactive carrier state to
progressive chronic hepatitis B (CHB), which may evolve to cir-
rhosis and hepatocellular carcinoma (HCC) [2–4]. HBV-related
end stage liver disease or HCC are responsible for over 0.5–1 mil-
lion deaths per year and currently represent 5–10% of cases of
liver transplantation [5–8]. Host and viral factors, as well as coin-
fection with other viruses, in particular hepatitis C virus (HCV),
hepatitis D virus (HDV), or human immunodeﬁciency virus
(HIV) together with other co-morbidities including alcohol abuse
and obesity, can affect the natural course of HBV infection as well
as efﬁcacy of antiviral strategies [2–8]. CHB may present either as
hepatitis B e antigen (HBeAg)-positive or HBeAg-negative CHB.
The prevalence of the HBeAg-negative form of the disease hasJournal of Hepatology 20
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Liver).been increasing over the last decade as a result of aging of the
HBV-infected population and predominance of speciﬁc HBV
genotypes and represents the majority of cases in many areas,
including Europe [4,9,10]. Morbidity and mortality in CHB are
linked to persistence of viral replication and evolution to cirrhosis
and/or hepatocellular carcinoma (HCC). Longitudinal studies of
untreated patients with CHB indicate that, after diagnosis, the
5-year cumulative incidence of developing cirrhosis ranges
from 8% to 20%. The 5-year cumulative incidence of hepatic
decompensation is approximately 20% for untreated patients
with compensated cirrhosis [2–4,11–13]. Untreated patients with
decompensated cirrhosis have a poor prognosis with a 14–35%
probability of survival at 5 years [2–4,12]. The worldwide inci-
dence of HCC has increased, mostly due to persistent HBV and/
or HCV infections; presently it constitutes the ﬁfth most common
cancer, representing around 5% of all cancers. The annual inci-
dence of HBV-related HCC in patients with CHB is high, ranging
from 2% to 5% when cirrhosis is established [13]. However, the
incidence of HBV related HCC appears to vary geographically
and correlates with the underlying stage of liver disease and pos-
sibly exposure to environmental carcinogens such as aﬂatoxin.
Population movements and migration are currently changing
the prevalence and incidence of the disease in several low ende-
mic countries in Europe and elsewhere. Substantial healthcare
resources will be required for control of the worldwide burden
of disease.
Natural history
Chronic HBV infection is a dynamic process. The natural history
of chronic HBV infection can be schematically divided into ﬁve
phases, which are not necessarily sequential.
(1) The ‘‘immune tolerant’’ phase is characterised by HBeAg
positivity, high levels of HBV replication (reﬂected by high
levels of serum HBV DNA), normal or low levels of amino-
transferases, mild or no liver necroinﬂammation and no or
slow progression of ﬁbrosis [2,3,6,8]. During this phase, the
rate of spontaneous HBeAg loss is very low. This ﬁrst phase
is more frequent and more prolonged in subjects infected
perinatally or in the ﬁrst years of life. Because of high lev-
els of viremia, these patients are highly contagious.
(2) The ‘‘immune reactive HBeAg-positive phase’’ is character-
ised by HBeAg positivity, relatively lower level of replica-
tion compared to the immune tolerant phase (as
reﬂected by lower serum HBV DNA levels), increased or12 vol. 57 j 167–185
Table 1. Grading of evidence and recommendations (adapted from the GRADE system) [32–37].
Grading of evidence Notes Symbol
High quality A
Moderate quality
of effect and may change the estimate
B
Low or very low quality
estimate of effect and is likely to change the estimate. Any estimate of effect is 
uncertain
C
Grading of recommendation Notes Symbol
Strong recommendation warranted
evidence, presumed patient-important outcomes, and cost
1
Weaker recommendation Variability in preferences and values, or more uncertainty: more likely a weak 
recommendation is warranted
Recommendation is made with less certainty; higher cost or resource consumption
2
Further research is very unlikely to change our confidence in the estimate of effect
Further research is likely to have an important impact on our confidence in the estimate
Further research is very likely to have an important impact on our confidence in the
Factors influencing the strength of the recommendation included the quality of the
Clinical Practice Guidelinesﬂuctuating levels of aminotransferases, moderate or severe
liver necroinﬂammation and more rapid progression of
ﬁbrosis compared to the previous phase [2–4,6,8]. This
phase may occur after several years of immune tolerance
(partial breakdown of tolerance) and is more frequently
and/or more rapidly reached in subjects infected during
adulthood, paralleling maturation of speciﬁc anti-HBV
immunity. It may last for several weeks to several years.
The rate of spontaneous HBeAg loss is enhanced. This
phase ends with seroconversion to anti-HBe.
(3) The ‘‘inactive HBV carrier state’’ may follow seroconver-
sion from HBeAg to anti-HBe antibody. It is characterised
by very low or undetectable serum HBV DNA levels and
normal serum aminotransferases. A minimum follow-up
of 1 year with alanine aminotransferase (ALT) levels at
least every 3–4 months and serum HBV DNA levels is
required before classifying a patient as inactive HBV car-
rier. ALT levels should remain persistently within the nor-
mal range according to traditional cut-off values
(approximately 40 IU/ml) [14] and HBV DNA should be
below 2000 IU/ml. Some inactive carriers, however, may
have HBV DNA levels greater than 2000 IU/ml (usually
below 20,000 IU/ml) accompanied by persistently normal
ALT levels [14–17]. Patients with HBV DNA <2000 IU/ml
and elevated ALT values should be usually advised to
undergo liver biopsy for the evaluation of the cause of liver
injury. As a result of immunological control of the infec-
tion, the inactive HBV carrier state confers a favourable
long-term outcome with a very low risk of cirrhosis or
HCC in the majority of patients [18–20]. HBsAg loss and
seroconversion to anti-HBs antibody may occur spontane-
ously in 1–3% of cases per year, usually after several years
with persistently undetectable HBV DNA [15]. On the other
hand, progression to CHB, usually HBeAg-negative, may
also occur [21]. Therefore, inactive HBV carriers should
be followed up for life with ALT determinations at least
every 6 months after the ﬁrst year and periodical measure-
ment of HBV DNA levels [14]. The follow-up should be clo-
ser in cases with baseline serum HBV DNA levels above
2000 IU/ml, in whom non-invasive evaluation of liver
ﬁbrosis may be useful and even liver biopsy might be
considered [14]. Inactive carriers have been reported to168 Journal of Hepatology 201have serum HBsAg levels <1000 IU/ml, but such HBsAg lev-
els may occasionally be detected in CHB patients as well
[22].
(4) ‘‘HBeAg-negative CHB’’ may follow seroconversion from
HBeAg to anti-HBe antibodies during the immune reactive
phase or may develop after years or decades of the inactive
carrier state. It represents a later immune reactive phase in
the natural history of chronic HBV infection. It is character-
ised by periodic reactivation with a pattern of ﬂuctuating
levels of HBV DNA and aminotransferases and active hepa-
titis [4,23–25]. These patients are HBeAg-negative and har-
bour a predominance of HBV virions with nucleotide
substitutions in the precore and/or the basal core promoter
regions that are hence unable to express or express low lev-
els of HBeAg. HBeAg-negative CHB is associated with low
rates of prolonged spontaneous disease remission [4,23]. It
is important and sometimes difﬁcult to distinguish true
inactive HBV carriers from patients with active HBeAg neg-
ative CHB in whom phases of spontaneous remission may
occur. The formerpatientshavea goodprognosiswith a very
low risk of complications, while the latter patients have
active liver disease with a high risk of progression to
advanced hepatic ﬁbrosis, cirrhosis and subsequent compli-
cations such as decompensated cirrhosis and HCC. A careful
assessment of the patients is needed and, as reported in the
inactive carrier state, a minimal follow-up of 1 year with
serum ALT levels every 3–4 months and HBV DNA levels
usually allows detection of ﬂuctuations of activity in
patients with active HBeAg-negative CHB [23].
(5) In the ‘‘HBsAg-negative phase’’ after HBsAg loss, low-level
HBV replication may persist with detectable HBV DNA in
the liver [26]. Generally, HBV DNA is not detectable in
the serum, while anti-HBc antibodies with or without
anti-HBs are detectable. HBsAg loss before the onset of cir-
rhosis is associated with improvement of the outcome
with reduced risk of cirrhosis, decompensation and HCC.
The clinical relevance of occult HBV infection [detectable
HBV DNA in the liver with low level (<200 IU/ml) or unde-
tectable HBV DNA in blood] is unclear [26]. Immunosup-
pression may lead to HBV reactivation in these patients
[27,28]. If cirrhosis has developed before spontaneous or
treatment-induced HBsAg loss, patients remain at risk of2 vol. 57 j 167–185
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HCC [29–31] and therefore HCC surveillance should con-
tinue (C2), although the cost-effectiveness of surveillance
has not been determined in this setting.Methodology
These EASL CPGs represent an update of the last EASL HBV CPGs
published in early 2009. They were developed by a CPG Panel of
experts chosen by the EASL Governing Board, peer-reviewed by
the experts of the 2009 HBV CPGs and approved by the EASL Gov-
erning Board. The CPGs have been based as far as possible on evi-
dence from existing publications, and, if evidence was
unavailable, on the experts’ personal experience and opinion.
Manuscripts and abstracts of important meetings published prior
to September 2011 have been evaluated. The evidence and rec-
ommendations in these guidelines have been graded according
to the Grading of Recommendations Assessment Development
and Evaluation (GRADE) system. The strength of recommenda-
tions thus reﬂects the quality of underlying evidence. The princi-
ples of the GRADE system have been enunciated. The quality of
the evidence in these CPGs has been classiﬁed in one of three lev-
els: high (A), moderate (B) or low (C). The GRADE system offers
two grades of recommendation: strong (1) or weak (2) (Table
1). The CPGs thus consider the quality of evidence: the higher
the quality of evidence, the more likely a strong recommendation
is warranted; the greater the variability in values and prefer-
ences, or the greater the uncertainty, the more likely a weaker
recommendation is warranted [32–37]. Grades are not provided
for deﬁnitions. For practical reasons, months and not weeks were
used in parts of the manuscript (e.g. 6 and 12 months instead of
24 and 48/52 weeks, respectively).The CPG panel members considered the
following questions: 
• How should liver disease be assessed before therapy?
• What are the goals and end points of treatment?
• 
• 
• What are the predictors of response?
• 
how should resistance be managed?
• How should treatment be monitored?
• When can treatment be stopped?
• How should special groups be treated?
• What are the current unresolved issues?
What are the definitions of response?
What is the optimal approach to first-line treatment?
What definitions of resistance should be applied andGuidelines
Pre-therapeutic assessment of liver disease
As a ﬁrst step, the causal relationship between chronic HBV infec-
tion and liver disease has to be established and an assessment ofJournal of Hepatology 201the severity of liver disease needs to be performed. In addition, all
ﬁrst degree relatives and sexual partners of patients with chronic
HBV infection should be advised to be tested for HBV serological
markers (HBsAg, anti-HBc, anti-HBs) and to be vaccinated if they
are negative for these markers (A1).
Not all patients with chronic HBV infection have persistently
elevated aminotransferases. Patients in the immune tolerant
phase and inactive carriers have persistently normal ALT levels,
while a proportion of patients with HBeAg-negative CHB may
have intermittently normal ALT levels. Therefore, appropriate
longitudinal long-term follow-up is crucial.
(1) The assessment of the severity of the liver disease should
include: biochemical markers, including aspartate amino-
transferase (AST) and ALT, gamma-glutamyl transpepti-
dase (GGT), alkaline phosphatase, bilirubin, and serum
albumin and globulins, blood counts and prothrombin
time, and hepatic ultrasound (A1). Usually, ALT levels are
higher than those of AST. However, when the disease pro-
gresses to cirrhosis, the ratio may be reversed. A progres-
sive decline in serum albumin concentrations and/or
increase of (gamma-)globulins and prolongation of the
prothrombin time, often accompanied by declining plate-
let counts, are characteristically observed after cirrhosis
has developed.
(2) HBV DNA detection and HBV DNA level measurement are
essential for the diagnosis, decision to treat and subse-
quent monitoring of patients (A1). Follow-up using real-
time PCR quantiﬁcation assays is strongly recommended
because of their sensitivity, speciﬁcity, accuracy and broad
dynamic range [38–41] (A1). The World Health Organiza-
tion (WHO) has deﬁned an international standard for nor-
malisation of expression of HBV DNA concentrations [42].
Serum HBV DNA levels should be expressed in IU/ml to
ensure comparability; the same assay should be used in
the same patient to evaluate antiviral efﬁcacy. All HBV
DNA values in this manuscript are reported in IU/ml; val-
ues given as copies/ml were converted to IU/ml by dividing
by a factor of 5.
(3) Other causes of chronic liver disease should be systemati-
cally looked for including co-infections with HDV, HCV
and/or HIV (A1). Patients with chronic HBV infection
should be also tested for antibody against hepatitis A virus
(anti-HAV) and should be advised to be vaccinated against
HAV if they are anti-HAV negative. Co-morbidities, includ-
ing alcoholic, autoimmune, metabolic liver disease with
steatosis or steatohepatitis should be assessed (A1).
(4) A liver biopsy is often recommended for determining the
degree of necroinﬂammation and ﬁbrosis since hepatic
histology can assist the decision to start treatment (A1).
The indications for liver biopsy are reported within the indica-
tions for treatment. The biopsy is also useful for evaluating other
possible causes of liver disease such as fatty liver disease.
Although liver biopsy is an invasive procedure, the risk of severe
complications is very low (1/4000–10,000). It is important that
the size of the needle biopsy specimen is large enough to accu-
rately assess the degree of liver injury, in particular ﬁbrosis
[43] (A1). A liver biopsy is usually not required in patients with
clinical evidence of cirrhosis or in those in whom treatment is
indicated irrespective of the grade of activity or the stage of2 vol. 57 j 167–185 169
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ﬁbrosis (A1). There is growing interest in the use of non-invasive
methods, including serummarkers and transient elastography, to
assess hepatic ﬁbrosis to complement or avoid a liver biopsy
[44–51]. Transient elastography, which is a non-invasive method
widely used in Europe, offers high diagnostic accuracy for the
detection of cirrhosis, although the results may be confounded
by severe inﬂammation associated with high ALT levels and the
optimal cut-off of liver stiffness measurements vary among stud-
ies [52,53].
Goal of therapy
The goal of therapy for CHB is to improve quality of life and sur-
vival by preventing progression of the disease to cirrhosis,
decompensated cirrhosis, end-stage liver disease, HCC and death.
This goal can be achieved if HBV replication can be suppressed in
a sustained manner. Then, the accompanying reduction in histo-
logical activity of CHB lessens the risk of cirrhosis and decreases
the risk of HCC, particularly in non-cirrhotic patients [54] (B1).
However, chronic HBV infection cannot be completely eradicated
due to the persistence of covalently closed circular DNA (cccDNA)
in the nucleus of infected hepatocytes, which may explain HBV
reactivation [26,55,56]. Moreover, the HBV genome integrates
into the host genome and might favour oncogenesis and the
development of HCC [57–59].
End points of therapy
Therapy must ensure a degree of virological suppression that
will then lead to biochemical remission, histological improve-
ment and prevention of complications. The ideal end point is
HBsAg loss, which however is infrequently achievable with
the currently available anti-HBV agents. A more realistic end
point is the induction of sustained or maintained virological
remission.
(1) In HBeAg-positive and HBeAg-negative patients, the ideal
end point is sustained off-therapy HBsAg loss, with or even
without seroconversion to anti-HBs. This is associated with
a complete and deﬁnitive remission of the activity of CHB
and an improved long-term outcome (A1).
(2) Induction of sustained off-therapy virological and bio-
chemical response in HBeAg-negative patients (either
HBeAg-positive cases at baseline with durable anti-HBe
seroconversion or HBeAg-negative cases from baseline) is
a satisfactory end point, because it has been shown to be
associated with improved prognosis (A1).
(3) A maintained virological remission (undetectable HBV
DNA by a sensitive PCR assay) under long-term antiviral
therapy in HBeAg-positive patients who do not achieve
anti-HBe seroconversion and in HBeAg-negative patients
is the next most desirable end point (A1).Deﬁnitions of response
Responses can be divided into biochemical, serological, virologi-
cal and histological. All responses can be estimated at several
time points during and after therapy. The deﬁnitions of virologi-
cal responses vary according to the timing (on or after therapy)
and type of therapy. Two different types of drugs can be used
in the treatment of CHB: conventional or pegylated interferon170 Journal of Hepatology 201alpha (IFN or PEG-IFN) and nucleoside/nucleotide analogues
referred to collectively as NAs in this document.
Biochemical response is deﬁned as normalisation of ALT levels.
It can be evaluated at several time points on-therapy, at the end
and after the end of therapy. Since ALT activity often ﬂuctuates
over time, a minimum follow-up of at least 1 year post-treatment
with ALT determinations at least every 3 months is required to
conﬁrm sustained off-treatment biochemical response (B1). It
should be noted that the rates of sustained off-treatment bio-
chemical responses may sometimes be difﬁcult to evaluate, as
transient (usually 63 months duration) ALT elevations before
long-term biochemical remission may occur in some CHB
patients within the ﬁrst year after treatment discontinuation. In
such cases, additional close ALT follow-up of at least 2 years after
ALT elevation seems to be reasonable in order to conﬁrm sus-
tained off-therapy biochemical remission (C2).
Serological response for HBeAg applies only to patients with
HBeAg-positive CHB and is deﬁned as HBeAg loss and serocon-
version to anti-HBe.
Serological response for HBsAg applies to all CHB patients and is
deﬁned as HBsAg loss and development of anti-HBs.
Virological responses on IFN/PEG-IFN therapy:
 Primary non-response has not been well established.
 Virological response is deﬁned as an HBV DNA concentra-
tion of less than 2000 IU/ml. It is usually evaluated at
6 months and at the end of therapy as well as at 6 and
12 months after the end of therapy.
 Sustained off-treatment virological response is deﬁned as
HBV DNA levels below 2000 IU/ml for at least 12 months
after the end of therapy.
Virological responses on NA therapy:
 Primary non-response is deﬁned as less than 1 log10 IU/ml
decrease in HBV DNA level from baseline at 3 months of
therapy.
 Virological response is deﬁned as undetectable HBV DNA
by a sensitive PCR assay. It is usually evaluated every 3–
6 months during therapy depending on the severity of
liver disease and the type of NA.
 Partial virological response is deﬁned as a decrease in HBV
DNA of more than 1 log10 IU/ml but detectable HBV DNA
after at least 6 months of therapy in compliant patients.
 Virological breakthrough is deﬁned as a conﬁrmed
increase in HBV DNA level of more than 1 log10 IU/ml com-
pared to the nadir (lowest value) HBV DNA level on ther-
apy; it may precede a biochemical breakthrough,
characterised by an increase in ALT levels. The main
causes of virological breakthrough on NA therapy are poor
adherence to therapy and/or selection of drug-resistant
HBV variants (resistance) (A1).
 HBV resistance to NA(s) is characterised by selection of
HBV variants with aminoacid substitutions that confer
reduced susceptibility to the administered NA(s). Resis-
tance may result in primary non-response or virological
breakthrough on therapy (A1).
 NA(s) discontinuation is not common practice to date.
However, NA(s) may be discontinued in some patients.
Sustained off-treatment virological response may be2 vol. 57 j 167–185
Table 2. Results of main studies for the treatment of HBeAg-positive chronic hepatitis B at 6 months following 12 months (48 or 52 weeks) of pegylated interferon
alpha (PEG-IFN) and at 12 months (48 or 52 weeks) of nucleos(t)ide analogue therapy.
PEG-IFN Nucleoside analogues Nucleotide analogues
PEG-IFN-2a PEG-IFN-2b Lamivudine Telbivudine Entecavir Adefovir Tenofovir
Dose* 180 µg 100 µg 100 mg 600 mg 0.5 mg 10 mg 245 mg
[Ref.] [63] [64] [63, 65-68] [68] [67] [69, 70] [70]
Anti-HBe seroconversion (%) 32 29 16-18 22 21 12-18 21
HBV DNA <60-80 IU/ml (%) 14 7 36-44 60 67 13-21 76
ALT normalisation# (%) 41 32 41-72 77 68 48-54 68
HBsAg loss (%) 3 7 0-1 0.5 2 0 3
⁄PEG-IFN were given as percutaneous injections once weekly and nucleos(t)ide analogues as oral tablets once daily.
#The deﬁnition of ALT normalisation varied among different trials (i.e. decrease of ALT to 61.25-times the upper limit of normal (ULN) in the entecavir or 61.3-times the
ULN in the telbivudine trial).
JOURNAL OF HEPATOLOGYdeﬁned similarly to the deﬁnition used for IFN therapy,
which requires HBV DNA values below 2000 IU/ml for at
least 12 months after treatment discontinuation.
Histological response is deﬁned as decrease in necroinﬂamma-
tory activity (by P2 points in HAI or Ishak’s system) without
worsening in ﬁbrosis compared to pre-treatment histological
ﬁndings.
Complete response is deﬁned as sustained off-treatment viro-
logical response together with loss of HBsAg.
Indications for treatment
The indications for treatment are generally the same for both
HBeAg-positive and HBeAg-negative CHB. This is based mainly
on the combination of three criteria:
 Serum HBV DNA levels.
 Serum ALT levels.
 Severity of liver disease.
Patients should be considered for treatment when they have
HBV DNA levels above 2000 IU/ml, serum ALT levels above the
upper limit of normal (ULN) and severity of liver disease assessed
by liver biopsy (or non-invasive markers once validated in HBV-
infected patients) showing moderate to severe active necroin-
ﬂammation and/or at least moderate ﬁbrosis using a standardised
scoring system (A1). In patients who fulﬁl the above criteria for
HBV DNA and histological severity of liver disease, treatment
may be initiated even if ALT levels are normal (A1). Indications
for treatment may also take into account age, health status, fam-
ily history of HCC or cirrhosis and extrahepatic manifestations.
The need for liver biopsy and treatment should be considered
separately in the following subgroups of patients:
 Immunotolerant patients: HBeAg-positive patients under
30 years of age with persistently normal ALT levels and a
high HBV DNA level, without any evidence of liver disease
and without a family history of HCC or cirrhosis, do not
require immediate liver biopsy or therapy. Follow-up at
least every 3–6 months is mandatory (B1). Consider liver
biopsy or even therapy in such patients over 30 years of
age and/or with a family history of HCC or cirrhosis.Journal of Hepatology 201 HBeAg-negative patients with persistently normal ALT
levels (ALT determinations at least every 3 months for at
least 1 year) and HBV DNA levels above 2000 but below
20,000 IU/ml, without any evidence of liver disease, do
not require immediate liver biopsy or therapy (B1). Close
follow-up with ALT determinations every 3 months and
HBV DNA every 6–12 months for at least 3 years is manda-
tory (C1). After 3 years, they should be followed for life
like all inactive chronic HBV carriers. Evaluation of the
severity of ﬁbrosis by a non-invasive method, such as
Fibroscan, might be useful in such cases (C2).
 Patients with obviously active CHB: HBeAg-positive and
HBeAg-negative patients with ALT above 2 times ULN
and serum HBV DNA above 20,000 IU/ml may start treat-
ment even without a liver biopsy (B1). In such patients,
liver biopsy may provide additional useful information,
but it does not usually change the decision for treatment.
A non-invasive method for the estimation of the extent of
ﬁbrosis and most importantly to conﬁrm or rule out cir-
rhosis is extremely useful in patients who start treatment
without liver biopsy (B1).
 Patients with compensated cirrhosis and detectable HBV
DNA must be considered for treatment even if ALT levels
are normal (B1).
 Patients with decompensated cirrhosis and detectable
HBV DNA require urgent antiviral treatment with NA(s).
Signiﬁcant clinical improvement can be associated with
control of viral replication [60–62]. However, antiviral
therapy may not be sufﬁcient to rescue some patients with
very advanced liver disease who should be considered for
liver transplantation at the same time (A1).Results of current therapies
Drugs available for the treatment of CHB include IFN, PEG-IFN
and six NAs. NAs for HBV therapy can be classiﬁed into nucleo-
sides (lamivudine, telbivudine, emtricitabine, entecavir) and
nucleotides (adefovir and tenofovir). PEG-IFN-2b and emtricita-
bine are not licensed for HBV treatment in most European coun-
tries. Lamivudine, adefovir, entecavir, telbivudine and tenofovir
have been approved in Europe for HBV treatment, and the com-
bination of tenofovir and emtricitabine in one tablet has been
licensed for the treatment of human HIV infection. The efﬁcacy
of these drugs has been assessed in randomized controlled trials2 vol. 57 j 167–185 171
Table 3. Results of main studies for the treatment of HBeAg-negative chronic hepatitis B at 6 months following 12 months (48 weeks) of pegylated interferon alpha
(PEG-IFN) and at 12 months (48 or 52 weeks) of nucleos(t)ide analogue therapy.
PEG-IFN Nucleoside analogues Nucleotide analogues
PEG-IFN-2a Lamivudine Telbivudine Entecavir Adefovir Tenofovir
Dose* 180 µg 100 mg 600 mg 0.5 mg 10 mg 245 mg
[Ref.] [91] [68, 90-92] [68] [92] [70, 93] [70]
HBV DNA <60-80 IU/ml (%) 19 72-73 88 90 51-63 93 
ALT normalisation# (%) 59 71-79 74 78 72-77 76 
HBsAg loss (%) 4 0 0 0 0 0
⁄PEG-IFN-2a was given as percutaneous injections once weekly and nucleos(t)ide analogues as oral tablets once daily.
#The deﬁnition of ALT normalisation varied among different trials (i.e. decrease of ALT to 61.25-times the upper limit of normal (ULN) in the entecavir or 61.3-times the
ULN in the telbivudine trial).
Clinical Practice Guidelinesat 1 year (2 years with telbivudine). Longer-term results are now
available from extension of the randomized trials sometimes in
patient subgroups and several cohort studies. Tables 2 and 3
show the response rates with these drugs from different trials.
These trials used different HBV DNA assays and there are not
head-to-head comparisons for all the drugs.
(1) HBeAg-positive patients
Response rates at 6 months following 12 months of PEG-IFN
and at 12 months of NA therapy are given in Table 2 [63–70].
Anti-HBe seroconversion rates were of the order of 30% with
PEG-IFN and approximately 20% with NAs. A 6-month course of
PEG-IFN-2a and/or a lower dose are inferior to the recommended
12-month course [71]. Anti-HBe seroconversion rates are
enhanced during the ﬁrst 6 months following PEG-IFN therapy
[63,72]. Anti-HBe seroconversion rates increase with continued
NA therapy [73–78], but are affected if resistance occurs [79].
Anti-HBe seroconversion is less durable after discontinuation of
NA compared to PEG-IFN therapy [79–82] (B1). Durability after
anti-HBe seroconversion following treatment with more potent
agents, i.e. entecavir and tenofovir, requires further evaluation.
In patients adherent to treatment, virological remission rates
of >90% can be maintained with ongoing entecavir or tenofovir
after P3 years [78,83–85].
Rates of HBsAg loss following 12 months of treatment were 3–
7% with PEG-IFN, 1% with lamivudine, 0% with adefovir, 2% with
entecavir, 0.5% with telbivudine, and 3% with tenofovir [63–70].
HBsAg loss rates increase after the end of (PEG-)IFN therapy in
patients with sustained off-treatment virological response [72,86–
88] and with prolongation of NA(s) therapy [77,78,84,85,89].
(2) HBeAg-negative patients
Response rates at 6 months following 12 months of PEG-IFN
and at 12 months of NA therapy are given in Table 3 [68,70,90–
93]. Rates of sustained off-treatment virological response were
of the order of 20% at 6 months following 12 months of PEG-
IFN therapy and <5% following discontinuation of 12 months of
NA(s) therapy [90–92,94,95]. In patients adherent to treatment,
virological remission rates of >95% can be maintained with ente-
cavir or tenofovir at P3–5 years [84,96].
Rates of HBsAg loss following 12 months of treatment were 3%
with PEG-IFN-2a (at 6 months after the end of therapy) and 0%
with lamivudine, adefovir, entecavir, telbivudine or tenofovir
[68,70,90–93]. HBsAg loss rates increase to 9% at 3 years and
12% at 5 years following PEG-IFN-2a therapy [97,98]. In contrast,172 Journal of Hepatology 201HBsAg loss is exceptionally observed during the ﬁrst 4–5 years of
NA(s) therapy in HBeAg-negative CHB patients [77,84,99,100].
Predictors of response
Certain general baseline and on-treatment predictors of subse-
quent response have been identiﬁed. Predictors of response for
the existing antiviral therapies at various time points vary for dif-
ferent agents. Predictors may be useful to guide initiation and
continuation of antiviral therapy.
(1) For IFN/PEG-IFN based treatment
 Pre-treatment factors
In HBeAg-positive CHB, predictors of anti-HBe seroconver-
sion are lowviral load (HBVDNAbelow2  108 IU/ml), high
serumALT levels (above 2–5 timesULN), HBV genotype and
high activity scores on liver biopsy (at least A2)
[63,64,101,102] (B2). HBV genotypes A and B have been
shown to be associated with higher rates of anti-HBe sero-
conversion and HBsAg loss than genotypes D and C, respec-
tively, after treatment with PEG-IFN [63,64,103,104].
In HBeAg-negative CHB, there are no strong pre-treatment
predictors of virological response.
 During treatment
In HBeAg-positive CHB, a HBV DNA decrease to <20,000 IU/
ml at 12 weeks is associated with a 50% chance of anti-HBe
seroconversion [105] and immunologically induced ALT
ﬂares followed by a HBV DNA decrease are associated with
more frequent anti-HBe seroconversion [106] (B2). Recent
data showed that decline of HBsAg levels below 1500 IU/
ml at 12 weeks is a strongpredictor of anti-HBe seroconver-
sion [107,108] (C2), whileHBsAg levels >20,000 IU/ml or no
decline of HBsAg levels at 12 weeks are associated with a
very low probability of subsequent anti-HBe seroconver-
sion [107–109] (C2). HBeAg levels at week 24may also pre-
dict anti-HBe seroconversion [105] (B2).
In HBeAg-negative CHB, HBV DNA decrease to <20,000 IU/
ml at 12 weeks has been reported to be associated with a
50% chance of sustained off-treatment response [110]. A
combination of no HBsAg decline and <2 log10 IU/ml
decline of HBV DNA seems to be a predictor of non-
response in European HBeAg-negative patients with geno-
type D [111,112] (B2). Several recent reports showed that
HBsAg decline is predictive of sustained off-treatment
virological response and HBsAg loss [113–115]. However,2 vol. 57 j 167–185
Table 4. Main respective advantages and disadvantages of (pegylated) interferon alpha [(PEG-)IFN] and nucleos(t)ide analogues (NAs) in the treatment of chronic
hepatitis B.
(PEG-)IFN NAs
Advantages • Finite duration
• Absence of resistance
• Higher rates of anti-HBe and anti-HBs seroconversion 
with 12 mo of therapy 
• Potent antiviral effect
• Good tolerance
• Oral administration
Disadvantages • Moderate antiviral effect
• Inferior tolerability
• Risk of adverse events
• Subcutaneous injections
•  duration
• Risk of resistance
• Unknown long-term safety
100
Year 1
Year 2
JOURNAL OF HEPATOLOGYfurther studies are needed to clarify how to optimise the
use of HBsAg levels in the management of patients in clin-
ical practice.Pe
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Fig. 1. Cumulative incidence of HBV resistance to lamivudine (LAM), adefovir
(ADV), entecavir (ETV), telbivudine (LdT) and tenofovir (TDF) in pivotal trials
in nucleos(t)ide-naive patients with chronic hepatitis B. For method of
calculation, see Ref. [41]. These trials included different populations, used
different inclusion and exclusion criteria and different follow-up end points.(2) For NAs treatment
 Pre-treatment factors
In HBeAg-positive CHB, pre-treatment factors predictive of
anti-HBe seroconversion are low viral load (HBV DNA
below 2  108 IU/ml), high serum ALT levels, high activity
scores on liver biopsy [69,70,77,116] (A1).
HBVgenotypedoesnot inﬂuence thevirological response to
any NA [117] (A1).
 During treatment
Virological response (undetectable HBV DNA) at 24 weeks
during treatment with lamivudine or telbivudine and at
48 weeks during treatmentwith adefovir is associatedwith
a lower incidence of resistance, i.e. an improved chance of
maintained virological response, in both HBeAg-positive
and HBeAg-negative patients and with a higher chance of
anti-HBe seroconversion in HBeAg-positive patients
[77,100,118,119] (B1).
A decline of HBsAg during NA treatment in HBeAg-positive
patients may identify cases with subsequent HBeAg or
HBsAg loss [120–122] (C2).
Treatment strategies: how-to-treat
Currently, there are two different treatment strategies for both
HBeAg-positive and HBeAg-negative CHB patients: treatment of
ﬁnite duration with (PEG-)IFN or a NA and long-term treatment
with NA(s).
The main theoretical advantages of (PEG-)IFN are the absence
of resistance and the potential for immune-mediated control of
HBV infection with an opportunity to obtain a sustained virolog-
ical response off-treatment and a chance of HBsAg loss in patients
who achieve and maintain undetectable HBV DNA. Frequent side
effects and subcutaneous injection are the main disadvantages of
(PEG-)IFN treatment. (PEG-)IFN is contraindicated in patients
with decompensated HBV-related cirrhosis or autoimmune dis-
ease, in patients with uncontrolled severe depression or psycho-
sis, and in female patients during pregnancy (A1).
Entecavir and tenofovir are potent HBV inhibitors with a high
barrier to resistance [67,70,78,85,92,123] (Fig. 1). Thus, they can
be conﬁdently used as ﬁrst-line monotherapies [1] (A1).
The other three NAs may only be used in the treatment of CHB
if more potent drugs with high barrier to resistance are not avail-Journal of Hepatology 201able or appropriate (A1). Lamivudine is an inexpensive agent, but
engenders very high rates of resistance with long-term mono-
therapy [124–127]. Adefovir is less efﬁcacious and more
expensive than tenofovir, engendering higher rates of resistance
[70,85,100]. Telbivudine is a potent inhibitor of HBV replication,
but, due to a lower barrier to resistance, a high incidence of resis-
tance has been observed in patients with high baseline HBV DNA
levels and in those with detectable HBV DNA after 6 months of
therapy [68,77]; resistance rates to telbivudine are relatively
low in patients with low baseline viremia (<2  108 IU/ml for
HBeAg-positive and <2  106 IU/ml for HBeAg-negative patients)
who achieve undetectable HBV DNA at 6 months of therapy
[77,128].
(1) Treatment of ﬁnite duration with (PEG-)IFN or a NA. This
strategy is intended to achieve a sustained off-treatment virolog-
ical response (A1).
 Finite-duration treatment with (PEG-)IFN. PEG-IFN, if
available, has replaced standard IFN in the treatment of
CHB mostly due to its easier applicability (once weekly
administration). A 48-week course of PEG-IFN is mainly
recommended for HBeAg-positive patients with the best
chance of anti-HBe seroconversion. It can also be used for
HBeAg-negative patients, as it is practically the only option2 vol. 57 j 167–185 173
Table 5. Cross-resistance data for the most frequent resistant HBV variants. The amino-acid substitution proﬁles are shown in the left column and the level of
susceptibility is given for each drug: S (sensitive), I (intermediate/reduced susceptibility), R (resistant) [139].
HBV variants Level of susceptibility
Lamivudine Telbivudine Entecavir Adefovir Tenofovir
Wild-type S S S S S
M204V R S I I S
M204I R R I I S
L180M + M204V R R I I S
A181T/V I S S R S
N236T S S S R I
L180M + M204V/I ± I169T ± V173L ± M250V R R R S S
L180M + M204V/I ± T184G ± S202I/G R R R S S
Clinical Practice Guidelinesthat may offer a chance for sustained off-treatment
response after a ﬁnite duration of therapy. Full information
about the advantages, adverse events and inconveniences
of (PEG-)IFN versus NAs (Table 4) should be provided so
the patient can participate in the decision (A1).
The combination of PEG-IFN with lamivudine showed a
higher on-treatment virological response but did not show
a higher rate of sustained off-treatment virological or
serological response [63,64,91]. The combination of
PEG-IFN with telbivudine showed a potent antiviral effect,
but it is prohibited because of a high risk of severe
polyneuropathy [129]. Thus, presently the combinations
of PEG-IFN with lamivudine or telbivudine are not
recommended (A1). There is limited information on the
efﬁcacy and safety of combination of PEG-IFN with other
NAs and presently this type of combination is not
recommended.
 Finite-duration treatment with a NA is achievable for
HBeAg-positive patients who seroconvert to anti-HBe on
treatment. However, treatment duration is unpredictable
prior to therapy as it depends on the timing of anti-HBe
seroconversion and the treatment continuation post
anti-HBe seroconversion. Anti-HBe seroconversion may
not be durable after NAs discontinuation, at least with less
potent agents, in a substantial proportion of these patients
requiring close virologic monitoring after treatment cessa-
tion. An attempt for ﬁnite NA treatment should use the
most potent agents with the highest barrier to resistance
to rapidly reduce levels of viremia to undetectable levels
and avoid breakthroughs due to HBV resistance (A1). Once
anti-HBe seroconversion occurs during NA administration,
treatment should be prolonged for an additional
12 months [130]; a durable off-treatment response (per-
sistence of anti-HBe seroconversion) can be expected in
40–80% of these patients [79,80,130–134] (B1).
(2) Long-term treatment with NA(s). This strategy is necessary
for patients who are not expected or fail to achieve a sustained
off-treatment virological response and require extended therapy,
i.e. for HBeAg-positive patients who do not develop anti-HBe
seroconversion and HBeAg-negative patients. This strategy is also
recommended in patients with cirrhosis irrespective of HBeAg
status or anti-HBe seroconversion on treatment (C1).174 Journal of Hepatology 201The most potent drugs with the optimal resistance proﬁle, i.e.
tenofovir or entecavir, should be used as ﬁrst-line monotherapies
(A1). It is optimal to achieve and maintain undetectable HBV DNA
level tested by real-time PCR, whatever the drug used (B1). The
long-term effects, safety and tolerability of entecavir and tenofo-
vir are still unknown. Treatment with either tenofovir or enteca-
vir monotherapy for P3 years achieves maintained virological
remission in the vast majority of patients [78,84,85] (A1).
There are as yet no data to indicate an advantage of de novo
combination treatment with NAs in NA naive patients receiving
either entecavir or tenofovir [135] (C1).
Treatment failure
It is important to distinguish between primary non-response,
partial virological response and virological breakthrough
[41,136].
(1) Primary non-response. Primary non-response is rarely
observed with entecavir or tenofovir, telbivudine or lamivudine.
In patients with primary non-response to any NA, it is important
to check for compliance. In a compliant patient with a primary
non-response, genotyping of HBV strains for identiﬁcation of pos-
sible resistance mutations may help in formulating a rescue strat-
egy that must reasonably be based on an early change to a more
potent drug that is active against the resistant HBV variant (B1).
Primary non-response seems to be more frequent with adefo-
vir (approximately 10–20%) than with other NAs because of
suboptimal antiviral efﬁcacy. In NA(s) naive patients with pri-
mary non-response to adefovir, a rapid switch to tenofovir or ent-
ecavir is recommended (B1).
(2) Partial virological response. Partial virological response may
be encountered with all available NAs. It is always important to
check for compliance.
In patients receiving lamivudine or telbivudine (drugs with a
low genetic barrier to resistance) with a partial virological
response at week 24 or in patients receiving adefovir (moderately
potent drug that engenders relatively late emergence of resis-
tance) with a partial response at week 48, change to a more
potent drug (entecavir or tenofovir), preferentially without
cross-resistance, is recommended (A1).
The optimal management of patients with partial virological
response under entecavir or tenofovir (highly potent drugs with
a high genetic barrier to resistance) is currently debatable. In2 vol. 57 j 167–185
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such patients with a partial virological response at week 48, the
HBV DNA levels at week 48 and their kinetics must be taken into
account. Patients with declining serum HBV DNA levels may con-
tinue treatment with the same agent (entecavir or tenofovir)
given the rise in rates of virological response over time and the
very low risk of resistance with long-term monotherapy with
both these agents [137] (B1). Some experts would suggest adding
the other drug in order to prevent resistance in the long term,
particularly in the rare patients without further HBV DNA decline
despite drug compliance (C2).
(3) Virological breakthrough. Virological breakthrough in com-
pliant patients is related to the development of HBV drug resis-
tance. Testing for genotypic resistance may be performed in
compliant patients with conﬁrmed virological breakthroughs,
although it is not absolutely necessary for NA naive patients with
conﬁrmed virological breakthroughs under monotherapy with
lamivudine or telbivudine (B1). Rates of resistance after up to
5 years of administration of the different NAs are shown in Fig. 1.
The rates of resistance at 5 years in NA naive patients are <1.5%
and 0% for entecavir and tenofovir, respectively [78,123]; thus,
virological breakthroughs in NA naive patients receiving entecavir
or tenofovir are usually due to poor drug compliance.
The risk of resistance is associated with high baseline HBV DNA
levels, a slowdecline inHBVDNAandsuboptimalpreviousNAtreat-
ment. Resistance should be identiﬁed by HBV DNA monitoring as
early as possible before biochemical breakthrough (increased ALT),
and ideally identiﬁcation of the pattern of resistance mutations
should be used to adapt therapeutic strategies. Indeed, clinical and
virological studies have demonstrated the beneﬁt of an early treat-
ment adaptation, as soon as viral load increases [99,138] (B1).
In case of resistance, an appropriate rescue therapy should be
initiated with the most effective antiviral agent that does not
share cross resistance to minimise the risk of inducing multiple
drug-resistant strains (A1). It should be noted that sequential
monotherapies with agents with low barriers and hence high or
intermediate risk of resistance (lamivudine, adefovir, telbivudine)
should be strictly avoided because of the high risk for emergence
of multi-drug resistance strains (C1). Table 5 shows cross-resis-
tance data for the most frequent resistant HBV variants [139].
In case of resistance to lamivudine, most experts based on the
current evidence suggest that switching to tenofovir is as effec-
tive as adding tenofovir to lamivudine [140]. In case of adefovir
resistance, a switch to entecavir or tenofovir or tenofovir plus
emtricitabine (in a single tablet) is an option [141,142]. The efﬁ-
cacy of tenofovir monotherapy has been reported to be subopti-
mal in patients with high serum HBV DNA levels due to
virological breakthroughs associated with adefovir resistance
[140]. In case of telbivudine resistance, a switch to or adding-
on tenofovir are the preferred options [136]. There are few data
for the treatment of the rare patients with entecavir resistance,
and therefore a switch to or adding-on tenofovir may be pre-
ferred in such cases [136]. To date, resistance to tenofovir has
not been described. It is recommended that genotyping and phe-
notyping should be done in such cases by an expert laboratory to
determine the cross-resistance proﬁle. In case of conﬁrmed ten-
ofovir resistance, an add-on combination with a nucleoside ana-
logue should be preferred, while a switch to entecavir may be
sufﬁcient if the patient had no prior lamivudine resistance. In
patients with multidrug resistance, genotypic resistance testing
is very useful and a combination of a nucleoside and a nucleotide
(preferably tenofovir) should be used.Journal of Hepatology 201 Lamivudine resistance: switch to tenofovir (add adefovir if
tenofovir is not available) (B1).
 Adefovir resistance: if the patient was NA naive before ade-
fovir, switch to entecavir or tenofovir (B1); entecavir may
be preferred in such patients with high viraemia (C2). If
the patient had prior lamivudine resistance, switch to ten-
ofovir and add a nucleoside analogue (C1).
 Telbivudine resistance: switch to or add tenofovir (add ade-
fovir if tenofovir is not available) (C1).
 Entecavir resistance: switch to or add tenofovir (add adefo-
vir if tenofovir is not available) (C1).
 Tenofovir resistance: tenofovir resistance has not been
detected to date and therefore there is no experience,
but it seems reasonable to add entecavir, telbivudine,
lamivudine or emtricitabine if tenofovir resistance is con-
ﬁrmed (C2). A switch to entecavir may be sufﬁcient if the
patient has not been treated with lamivudine in the past,
while adding entecavir may be the preferred option for
patients with prior lamivudine resistance (C2).How to monitor treatment and stopping points
Finite therapy with PEG-IFN
In patients treated with PEG-IFN, full blood counts and serum ALT
levels should be monitored monthly and TSH should be moni-
tored every 3 months. All patients should be monitored for safety
through 12 months of treatment.
 In HBeAg-positive patients, HBeAg and anti-HBe antibod-
ies and serum HBV DNA levels should be checked at 6
and 12 months of treatment and at 6 and 12 months
post-treatment. Sustained off-treatment anti-HBe serocon-
version together with ALT normalisation and serum HBV
DNA below 2000 IU/ml is the desired outcome (A1). Unde-
tectable serum HBV DNA by real-time PCR during follow-
up is the optimal outcome, since it is associated with a sig-
niﬁcant chance of HBsAg loss (B1). HBeAg-positive patients
who develop anti-HBe seroconversion with PEG-IFN
require long-term follow-up because of the possibility of
HBeAg seroreversion or progression to HBeAg-negative
CHB [81,82] (A1). HBsAg should be checked at 12-month
intervals after anti-HBe seroconversion if HBV DNA is
undetectable, as the rate of HBsAg loss increases over time
[87]. Patients who become HBsAg negative should be
tested for anti-HBs. Patients treated with PEG-IFN who
achieve quick reductions of HBV DNA and/or HBsAg levels
through 3 or 6 months of therapy have an increased prob-
ability of response. In contrast, HBeAg-positive patients
treated with PEG-IFNwho fail to achieve serumHBsAg lev-
els below 20,000 IU/ml or any decline in serum HBsAg lev-
els by month 3 have a low probability of achieving anti-
HBe seroconversion [107–109]; therefore, stopping PEG-
IFN therapy may be considered (C2).
 In HBeAg-negative patients, serum HBV DNA levels should
be measured at 6 and 12 months of treatment and at 6 and
12 months post-treatment. A sustained off-treatment viro-
logical response with HBV DNA <2000 IU/ml is generally
associated with remission of the liver disease. Undetect-
able HBV DNA by real-time PCR is the ideal desired sus-
tained off-treatment response with a higher probability2 vol. 57 j 167–185 175
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of HBsAg loss in the longer term. HBsAg should be checked
at 12-month intervals if HBV DNA remains undetectable
(B1). Patients who become HBsAg negative should be
tested for anti-HBs. HBeAg-negative patients who achieve
sustained off-treatment response at 12 months after a
PEG-IFN course require long-term follow-up, because there
is still a risk of future disease reactivation that seems to
diminish over time [143] (A1). HBeAg-negative patients,
in particular those with genotype D, treated with PEG-
IFN who fail to achieve any decline in serum HBsAg levels
and aP2 log10 IU/ml decline in serum HBV DNA levels by
month 3, have a very low probability of response; there-
fore, stopping PEG-IFN therapy should be considered
[111,112] (B2).Finite treatment with NAs in HBeAg-positive patients
The objective of ﬁnite treatment with a NA is sustained off-treat-
ment anti-HBe seroconversion with HBV DNA <2000 IU/ml and
normal ALT, or even HBsAg clearance (A1). HBeAg and anti-HBe
should be checked every 6 months. HBV DNA should be measured
by a sensitive PCR assay every 3–6 months during treatment. HBV
DNA suppression to undetectable levels in real-time PCR and sub-
sequent anti-HBe seroconversion is associated with biochemical
and histological responses. Studies have suggested that NA ther-
apy can be stopped 12 months after anti-HBe seroconversion
(B1). A proportion of patients who discontinue NA therapy after
anti-HBe seroconversion may require retreatment, since they fail
to sustain their serological and/or virological response
[79,80,131–134]. Therefore, NA treatment may be continued until
HBsAg clearancewith orwithout antibodies to HBsAg, particularly
in patients with severe ﬁbrosis or cirrhosis (C1). HBsAg should be
checked at 12-month intervals after anti-HBe seroconversion.
HBsAg loss, however, is not observed sufﬁciently frequently dur-
ing or after NA therapy (Table 2).Long-term therapy with NAs
HBV DNA reduction to undetectable levels by real-time PCR (i.e.
below 10–15 IU/ml) should ideally be achieved to avoid resis-
tance. HBV DNA monitoring is thus critical to detect treatment
failure (A1). HBV DNA levels should be monitored at month 3
to ascertain virological response and then every 3–6 months.
During therapy with entecavir or tenofovir, agents with high bar-
rier to resistance, the frequency of follow-up measurement of
HBV DNA might be decreased once patient compliance and treat-
ment efﬁcacy are conﬁrmed (C1).
NAs are cleared by the kidneys, and appropriate dosing adjust-
ments are recommended for patients with creatinine clear-
ance <50 ml/min (A1). Therefore, all patients starting NA
therapy should be tested for serum creatinine levels and esti-
mated creatinine clearance before treatment (A1). In addition,
the baseline renal risk should be assessed for all patients. High
renal risk includes one or more of the following factors: decom-
pensated cirrhosis, creatinine clearance <60 ml/min, poorly
controlled hypertension, proteinuria, uncontrolled diabetes,
active glomerulonephritis, concomitant nephrotoxic drugs, solid
organ transplantation. Minimal rates of renal function decline
have been reported with all NAs, except perhaps for telbivudine
which seems to improve the creatinine clearance [144] (C1). The
nephrotoxic potential seems to be higher for nucleotide ana-176 Journal of Hepatology 201logues, particularly adefovir [145] (B1). Therefore, it seems appro-
priate for now to monitor for adverse renal effects with serum
creatinine (estimated creatinine clearance) and serum phosphate
levels during adefovir or tenofovir therapy in all CHB patients and
with serum creatinine levels (estimated creatinine clearance) dur-
ing nucleoside analogue therapy in CHB patients at high renal risk
(C1). The frequency of renal monitoring can be every 3 months
during the ﬁrst year and every 6 months thereafter, in case of no
worsening, in patients at low renal risk as well as every month
for the ﬁrst 3 months, every 3 months until the end of the ﬁrst
year and every 6 months thereafter, in case of no worsening, in
patients at high renal risk (C2). Closer renal monitoring is required
in patients who develop creatinine clearance <60 ml/min or
serum phosphate levels <2 mg/dl) (C1).
Drug concentrations are comparable in patients with varying
degrees of hepatic impairment, but this has not been fully studied.
Decreases in bone mineral density have rarely been reported in
HIV-positivepatients treatedwith tenofovir. Studies to evaluatebone
densitometry inCHBpatientsunder tenofovirareongoing. Long-term
monitoring for carcinogenesis in CHB patients under entecavir is
ongoing. Myopathy has rarely been reported in CHB patients treated
with telbivudine. The long-term safety of several NAs combination
including tenofovir and entecavir is currently unknown.
Treatment of patients with severe liver disease
Treatment of patients with cirrhosis
PEG-IFN may increase the risk of bacteraemic infection and hepa-
tic decompensation in patients with advanced cirrhosis [146].
However, PEG-IFN in regimens similar to those used in CHB can
be used for the treatment of well compensated cirrhosis [147]
(A1). Among NAs, monotherapies with tenofovir or entecavir
are preferred because of their potency and minimal risk of resis-
tance [148,149] (A1). Lamivudine should not be used in such
patients. Close monitoring of HBV DNA levels every 3 months at
least during the ﬁrst year of therapy and until HBV DNA unde-
tectability is important, as exacerbations of hepatitis B may occur
in patients with cirrhosis requiring urgent management. Thus,
patients with cirrhosis require long-term therapy, with careful
monitoring for resistance and ﬂares.
Clinical studies indicate that prolonged and adequate sup-
pression of HBV DNA can stabilize patients and prevent the pro-
gression to decompensated liver disease [54,99] (A1). Regression
of ﬁbrosis and even reversal of cirrhosis have been reported in
patients with prolonged suppression of viral replication [150].
Nonetheless, long-term monitoring for HCC is mandatory despite
virological remission under NA(s), since there is still a risk of
developing HCC [151,152] (B1).
NA therapy shouldusuallybe continued indeﬁnitely in cirrhotic
patients. After at least 12 months of consolidation therapy, treat-
ment might be stopped in HBeAg-positive patients if they achieve
conﬁrmed anti-HBe seroconversion or ideally HBsAg loss and anti-
HBs seroconversion and inHBeAg-negative patients if they achieve
conﬁrmed HBsAg loss and anti-HBs seroconversion (B1).
Treatment of patients with decompensated cirrhosis
Patients with decompensated cirrhosis should be treated in spec-
ialised liver units, as the application of antiviral therapy is com-
plex, and these patients may be candidates for liver
transplantation. Antiviral treatment is indicated irrespective of
HBV DNA level in order to prevent reactivation.2 vol. 57 j 167–185
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(PEG-)IFN is contraindicated in this setting. Entecavir or ten-
ofovir should be used (A1). The licensed entecavir dose for
patients with decompensated cirrhosis is 1 mg (instead of
0.5 mg for patients with compensated liver disease) once daily.
Recent studies have shown that both drugs are not only effective
but generally safe in these patients, at least in the ﬁrst years of
therapy [60–62]. Lactic acidosis has been reported to develop in
some NA, particularly entecavir, treated patients with advanced
decompensated cirrhosis (MELD score >20) [153]. Therefore, clin-
ical and laboratory parameters should be closelymonitored in this
setting (A1). The dose of all NAs needs to be adjusted in patients
with low creatinine clearance (<50 ml/min) (A1).
Patients with decompensated cirrhosis may show slow clini-
cal improvement over a period of 3–6 months under NA(s) and
then transplantation may be avoided. In such cases, life-long
treatment is recommended. The HCC risk is high in these patients
even under effective NA therapy and therefore long-term HCC
surveillance is mandatory [152] (A1). Some patients with
advanced hepatic disease with a high Child–Pugh or MELD score
may have progressed beyond the point of no return, and may not
beneﬁt, thus requiring liver transplantation [154]. In that situa-
tion, treatment with NA(s) inducing HBV DNA undetectability
at transplantation will decrease the risk of HBV recurrence in
the graft [155].
Prevention of recurrent hepatitis B after liver transplantation
Recurrent HBV infection in the transplanted liver has previously
been a major problem. Pre-transplant therapy with a potent NA
with a high barrier to resistance is recommended for all HBsAg-
positive patients undergoing liver transplantation for HBV-
related end-stage liver disease or HCC, to achieve the lowest
possible level of HBV DNA before transplantation [155–158]
(A1). Lamivudine and/or adefovir in combination with hepatitis
B immunoglobulin (HBIg) have reduced the risk of graft infection
to less than 10% [155,157,158]. Shorter courses and lower doses
of HBIg and other forms of prophylaxis, including tenofovir with
emtricitabine or entecavir monotherapy, are being studied.
Recently, entecavir prophylaxis without HBIG was shown to be
safe and effective in preventing HBV recurrence [159]. Prelimin-
ary safety and efﬁcacy data with tenofovir and emtricitabine with
or without HBIG have also been reported [160]. In the setting of
liver transplantation, nephrotoxicity should be always considered
and renal function should be carefully monitored because of the
concomitant use of calcineurin inhibitors (C1).
Treatment in special patient groups
HIV co-infected patients
HIV-positive patients with CHB were at increased risk of cirrhosis
before HAART and a higher risk of HCC is suggested [161–167].
Treatment of HIV may lead to ﬂares of hepatitis B due to immune
reconstitution, but the risk of developing cirrhosis is negligible in
HBV/HIV co-infected patients on long-term tenofovir combined
with emtricitabine or lamivudine therapy [168]. The indications
for therapy are the same as in HIV-negative patients, based on
HBV DNA levels, serum ALT levels and histological lesions [169].
In agreement with recent HIV guidelines, it is recommended that
most co-infected patients should be simultaneously treated for
both HIV and HBV de novo [170]. Tenofovir combined with emtri-
citabine or lamivudine plus a third agent active against HIV areJournal of Hepatology 201indicated [170,171] (A1). The strong rationale for early dual anti-
HIV and anti-HBV therapy have simpliﬁed the recommendations
for widening the use of tenofovir and emtricitabine or lamivudine
in HBV–HIV co-infected patients, irrespective of immunological,
virological or histological considerations [172] (B1).
In a small number of patients with CD4 count >500/ml, HBV
can be treated before the institution of anti-HIV therapy; PEG-
IFN, adefovir and telbivudine, which are not proven to be active
against HIV, should be preferred [170]. However, if any of these
two NAs with a low barrier to resistance does not reach the goal
of undetectable HBV DNA after 12 months of therapy, treatment
of HIV infection should be envisaged. Lamivudine, entecavir and
tenofovir have activity against both HIV and HBV and are contra-
indicated as single agents for hepatitis B in co-infected patients
because of the risk of HIV resistance (A1). Thus, all HBsAg-posi-
tive patients should be screened for HIV before these drugs are
used in the treatment of HBV infection (A1).
HDV co-infected patients
Severe or fulminant hepatitis is more frequently observed in
HBV-HDV co-infection compared to HBV mono-infection [173].
Chronic infection after acute HBV-HDV hepatitis is less common,
while chronic delta hepatitis develops in 70–90% of patients with
HDV superinfection [173,174]. Active co-infection with HDV is
conﬁrmed by detectable HDV RNA, immuno-histochemical stain-
ing for HDV antigen, or IgM anti-HDV [174]. However, diagnosis
of active HDV infection may be difﬁcult, as HDV RNA assays are
not standardised and HDV antigen and IgM anti-HDV assays are
not widely available [174,175]. Persistent HDV replication leads
to cirrhosis and HCC at annual rates of 4% and 2.8% and is the
most important predictor of mortality evidencing the need of
antiviral therapy [173,176,177].
(PEG-)IFN is the only drug effective against HDV [178–183]
(A1). The efﬁcacy of (PEG-)IFN therapy can be assessed during
treatment (after 3–6 months) by measuring HDV RNA levels
(C2). More than 1 year of therapy may be necessary, as there
may be some beneﬁt from treatment prolongation [183,184]
(C2). However, the optimal duration of therapy is not well
deﬁned [173,174]. Around 25–40% of treated patients have a sus-
tained off-treatment virological response with undetectable HDV
RNA and accompanying improvement in histology, while some
also lose HBsAg [173,174,182]. However, it has not been deﬁned
how long patients need to be HDV RNA negative after the end of
therapy before sustained virological response is achieved. NAs do
not impact HDV replication and related disease [173,174]. How-
ever, NA treatment might be considered in some patients who
have active HBV replication with persistent or ﬂuctuating serum
HBV DNA levels above 2000 IU/ml [174,185,186].
HCV co-infected patients
In HBV-infected patients, HCV co-infection accelerates liver dis-
ease progression and increases the risk of HCC [187–189]. HBV
and HCV replicate in the same hepatocyte without interference
[190]. A proportion of these patients may have ﬂuctuating serum
HBV DNA levels, thus indicating the need for longitudinal evalu-
ation of viral loads before starting any antiviral therapy in order
to clarify the respective pathogenic role of each virus [185]. Nev-
ertheless, HBV DNA level is often low or undetectable and HCV is
responsible for the activity of chronic hepatitis in most patients,
although this is variable probably due to indirect mechanisms
mediated by innate and/or adaptive host immune responses2 vol. 57 j 167–185 177
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[190]. Thus, patients should usually receive treatment for HCV
[191] (B1). Sustained virological response rates for HCV are
broadly comparable with HCV mono-infected patients
[187,192–194]. There is a potential risk of HBV reactivation dur-
ing treatment or after clearance of HCV [191]. Therefore, HBV
DNA monitoring is necessary. Any HBV reactivation must then
be treated with NA(s) (B1).
Acute hepatitis
More than 95–99% of adults with acute HBV infection will
recover spontaneously and seroconvert to anti-HBs without anti-
viral therapy [195] (A1). Patients with fulminant or severe hepa-
titis must be evaluated for liver transplantation (A1). These
patients may beneﬁt from NA treatment. Support for such a strat-
egy may be found in a small number of reports mainly with lam-
ivudine [196]. As for CHB, entecavir or tenofovir should be used
(C1). The duration of treatment is not established. However, con-
tinuation of antiviral therapy for at least 3 months after serocon-
version to anti-HBs or at least 12 months after anti-HBe
seroconversion without HBsAg loss is recommended (C2).
Sometimes, the distinction between true severe acute hepati-
tis B and reactivation of CHB may be difﬁcult and may require
liver biopsy. However, NA treatment is the treatment of choice
in both cases [196–198] (B1).
Children
Chronic hepatitis B runs an asymptomatic course in most chil-
dren, in whom treatment indications should be very carefully
evaluated [199]. In general, a conservative approach is warranted
(A1). Only conventional IFN, lamivudine and adefovir have been
evaluated for safety and efﬁcacy, which were comparable to
adults [199–202]. There are ongoing studies with other NAs in
children to better deﬁne treatment strategies for children.
Healthcare workers
Healthcare workers need special attention, as they may require
antiviral therapy even if they do not fulﬁl the typical indications
for treatment to reduce direct transmission during exposure
prone procedures to patients. Policies for HBsAg-positive health-
care workers vary among countries. In many countries, health-
care workers, including surgeons, gynaecologists and dentists,
who are HBsAg-positive with HBV DNA P2000 IU/ml should be
treated with a potent antiviral agent with a high barrier to resis-
tance (i.e. entecavir or tenofovir), to reduce levels of HBV DNA
ideally to undetectable or at least to <2000 IU/ml before resum-
ing exposure-prone procedures (B1). Monitoring for compliance
and efﬁcacy in practicing surgeons is required. The long-term
safety, efﬁcacy, complications and economic implications of such
a policy are unknown [203].
Pregnancy
Family planning should be always discussed with women of
childbearing age before initiating HBV therapy. The woman
should be informed about the safety data of the drugs on a pos-
sible pregnancy (A1).
(PEG-)IFN is contraindicated during pregnancy (A1). Lamivu-
dine, adefovir and entecavir are listed by the FDA as pregnancy
category C drugs, and telbivudine and tenofovir as category B
drugs [204]. These classiﬁcations are based on the risk of terato-
genicity in preclinical evaluation. The safety of entecavir in preg-178 Journal of Hepatology 201nancy is not known. There is a considerable body of safety data
from the Antiretroviral Pregnancy Registry in pregnant HIV-posi-
tive women who have received tenofovir and/or lamivudine or
emtricitabine [205,206]. Among them, tenofovir should be pre-
ferred, because it has better resistance proﬁle and more extensive
safety data in pregnant, HBV positive women [205,206] (B1).
In a woman of childbearing age without advanced ﬁbrosis
who plans a pregnancy in the near future, it may be prudent to
delay therapy until the child is born (C1). In a woman of child-
bearing age with advanced ﬁbrosis or cirrhosis who agrees for a
‘‘planned pregnancy’’ in the future, (PEG-)IFN therapy may be
tried as it is given for a ﬁnite duration (C1). It should be noted
that effective contraception is required during (PEG-)IFN therapy.
If (PEG-)IFN is not possible or has failed, treatment with a NA has
to be initiated and maintained even during a future pregnancy
(C1). Tenofovir represents the most reasonable choice for such
female patients (B1).
If female patients become unexpectedly pregnant during anti-
HBV therapy, treatment indications should be reevaluated (C1).
The same treatment indications apply to women who are ﬁrst
diagnosed to have CHB during pregnancy (C1). Patients with
advanced ﬁbrosis or cirrhosis should deﬁnitely continue to be
treated, but the treating agent should be reconsidered (C1).
(PEG-)IFN must be stopped and the patients should continue on
a NA, while FDA category C NAs, particularly adefovir and enteca-
vir, should be changed to a FDA category B NA (C1). Among FDA
category B NAs, tenofovir is preferred because of its high potency,
high genetic barrier and available safety data in pregnancy (C1).
The prevention of HBV perinatal transmission, which is con-
sidered to occur mainly at delivery, is traditionally based on the
combination of passive and active immunisation with hepatitis
B immunoglobulin (HBIg) and HBV vaccination. Such a strategy,
however, may not be effective in a proportion of newborns from
highly viremic (serum HBV DNA >106–7 IU/ml), mostly HBeAg-
positive, mothers, who carry a >10% risk of vertical HBV transmis-
sion despite HBIg and vaccination [207–210]. Mothers with these
high concentrations of HBV DNA should be informed that utilis-
ing a NA to reduce their viral loads could add to the effectiveness
of HBIg and vaccination (B1). Lamivudine and recently telbivu-
dine therapy during the last trimester of pregnancy in pregnant
HBsAg-positive women with high levels of viremia have been
shown to be safe and to reduce the risk of intra-uterine and peri-
natal transmission of HBV if given in addition to passive and
active vaccination by HBIg and HBV vaccination [208,209,211–
213] (B1). Thus, telbivudine, lamivudine or tenofovir (as a potent
FDA category B agent) may be used for the prevention of perina-
tal and intra-uterine HBV transmission in the last trimester of
pregnancy in HBsAg-positive women with high levels of viremia
(serum HBV DNA >106–7 IU/ml) (B1). No controlled clinical trial
of tenofovir to prevent perinatal transmission has been con-
ducted. If NA therapy is given only for the prevention of perinatal
transmission, it may be discontinued within the ﬁrst 3 months
after delivery (C1).
If a pregnant woman remains untreated or anti-HBV therapy
is discontinued during pregnancy or early after delivery for any
reason, close monitoring of the patient is necessary, as there is
a risk of hepatic ﬂares, especially after delivery [214,215] (B1).
The safety of NA therapy during lactation is uncertain. HBsAg
can be detected in breast milk, but breast feeding may not be
considered a contraindication in HBsAg-positive mothers.
Tenofovir concentrations in breast milk have been reported, but2 vol. 57 j 167–185
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its oral bioavailability is limited and thus infants are exposed to
only small concentrations [216].Pre-emptive therapy before immunosuppressive therapy or
chemotherapy
In HBsAg-positive patients receiving chemotherapy or immuno-
suppressive therapy including the established and emerging
range of biological response modiﬁers, the risk of reactivation is
high, particularly if rituximab is given alone or in combination
with steroids [217–220]. Therefore, all candidates for chemother-
apy and immunosuppressive therapy should be screened for
HBsAg and anti-HBc prior to initiation of treatment (A1).
Vaccination of HBV seronegative patients is highly recom-
mended (A1). Higher vaccine doses may be required to achieve
anti-HBs response in immunocompromised patients.
HBsAg-positive candidates for chemotherapy and immuno-
suppressive therapy should be tested for HBV DNA levels and
should receive pre-emptive NA administration during therapy
(regardless of HBV DNA levels) and for 12 months after cessation
of therapy (A1). There are limited data on the optimal options.
Most experience with pre-emptive treatment has been with lam-
ivudine, which may sufﬁce for patients with low (<2000 IU/ml)
HBV DNA levels when a ﬁnite and short duration of immunosup-
pression is scheduled [221,222]. In this setting, prophylactic lam-
ivudine reduces the risk of HBV reactivation and the associated
morbidity and mortality (B1). It is, however, recommended that
patients, who have a high HBV DNA level and/or may receive a
lengthy and repeated cycles of immunosuppression, should be
protected with a NA with high antiviral potency and a high bar-
rier to resistance, i.e. entecavir or tenofovir (C1).
HBsAg-negative patients with positive anti-HBc antibodies
should be tested for HBV DNA. HBsAg-negative, anti-HBc positive
patients with detectable serum HBV DNA should be treated sim-
ilarly to HBsAg positive patients (C1).
HBsAg-negative, anti-HBc positive patients with undetectable
serum HBV DNA and regardless of anti-HBs status who receive
chemotherapy and/or immunosuppression should be followed
carefully by means of ALT and HBV DNA testing and treated with
NA therapy upon conﬁrmation of HBV reactivation before ALT
elevation (C1). The frequency of monitoring can range from 1–
3 months depending on the type of immunosuppressive therapy
and comorbidities. Some experts recommend prophylaxis with
lamivudine in all HBsAg-negative, anti-HBc positive patients
who receive rituximab and/or combined regimens for hematolog-
ical malignancies, if they are anti-HBs negative and/or if close
monitoring of HBV DNA is not guaranteed [220,223–225] (C2).
NA prophylaxis is also recommended for anti-HBc positive
patients receiving bone marrow or stem cell transplantation
[225,226] (C2). The optimal duration of prophylaxis for these
indications is not known.
HBsAg-negative recipients of liver grafts from anti-HBc posi-
tive donors should receive prophylaxis with lamivudine, which
should continue indeﬁnitely [227] (B1).Dialysis and renal transplant patients
HBV is prevalent in patientswith end-stage renal disease including
renal transplant patients. Patients with renal disease should be
screened for HBV infection. Though vaccine responsiveness is
impaired, HBV seronegative patients should be vaccinated. (PEG-
)IFN or NAs can be used for CHB patients with renal dysfunction.Journal of Hepatology 201All drugs and particularly NAs should be dose-adjusted (A1) and
used with caution in patients with renal impairment (B1). Accord-
ing to the approved drug SPCs, there is no recommended tenofovir
dose for non-hemodialysed patients with creatinine clear-
ance <10 ml/min. Renal function should bemonitored during anti-
viral treatment. Unexpected deterioration of renal function during
antiviral treatment may necessitate a change of treatment or fur-
ther dose adaptation. Hypertension and coexisting diabetes melli-
tus should be optimally controlled.
(PEG-)IFN should be avoided in renal transplant patients
because of the risk of rejection. Every HBsAg positive patient who
undergoes renal transplantation and receives immunosuppressive
agents should receive anti-HBV prophylaxis with a NA. The need
for antiviral prophylaxis or treatment shouldbe constantly and fre-
quently evaluated for all HBV positive renal transplant patients.
Extrahepatic manifestations
There is decreasing incidence of HBV related extrahepatic mani-
festations, such as skin manifestations, polyarteritis nodosa and
glomerulonephritis. HBsAg positive patients with extra-hepatic
manifestations and active HBV replication may respond to antivi-
ral therapy. (PEG)-IFN may worsen some immune mediated
extra-hepatic manifestations. Controlled studies of antiviral ther-
apy are limited, but case reports suggest that it may be of beneﬁt.
Lamivudine has been most widely used to date. Entecavir and
tenofovir are expected to have enhanced efﬁcacy in this group.
Plasmapheresis and corticosteroids during the initial phase can
be useful in addition to NA therapy in special cases (C2).Unresolved issues and unmet needs
(1) Improve knowledge and prognosis of the natural history
and indications for treatment, particularly in HBeAg-posi-
tive immunotolerant patients and HBeAg-negative
patients with serum HBV DNA levels below 20,000 IU/ml.
(2) Assess the role of non-invasive markers (serum and bio-
physical) for the evaluation of the severity of liver disease
and for the follow-up of treated and untreated patients.
(3) Further clarify the role of serum HBsAg levels in the eval-
uation of the natural history, prediction of therapeutic
responses and treatment individualisation.
(4) Assess host genetic and viral markers to determine prog-
nosis and optimise patients’ management.
(5) Assess the impact of early diagnosis and early treatment
intervention.
(6) Assess long-term safety and resistance to the current ﬁrst-
line NAs (entecavir and tenofovir).
(7) Identify markers that predict successful NA
discontinuation.
(8) Assess the safety and efﬁcacy of the combination of PEG-
IFN with a potent NA (entecavir or tenofovir) to increase
anti-HBe and anti-HBs seroconversion rates.
(9) Develop and assess new drugs and therapeutic approaches,
particularly immunomodulatory therapies, to enhance loss
of HBeAg and HBsAg and subsequent seroconversion.
(10) Assess long-term impact of therapy on the prevention of
cirrhosis and its complications and HCC.
(11) Develop strategies and identify subgroups for effective
HBIg free prophylaxis after liver transplantation for HBV
related liver disease.2 vol. 57 j 167–185 179
(12) Develop effective and optimum treatment for HDV
co-infection.Clinical Practice GuidelinesConﬂict of interest
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